ZM-182345

ZM-182345 is a nonsteroidal progestin that was never marketed.[1][2] It was derived from structural modification of the nonsteroidal antiandrogen hydroxyflutamide.[1][2] ZM-182345 was found to be at least as potent as progesterone as a progestogen in animals but to also possess androgenic activity.[1]

ZM-182345
Identifiers
  • 2-Hydroxy-N-[4-nitro-3-(trifluoromethyl)phenyl]-4-phenyl-2-(trifluoromethyl)pentanamide
PubChem CID
Chemical and physical data
FormulaC19H16F6N2O4
Molar mass450.337 g·mol−1
3D model (JSmol)
  • CC(CC(C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F)(C(F)(F)F)O)C2=CC=CC=C2
  • InChI=1S/C19H16F6N2O4/c1-11(12-5-3-2-4-6-12)10-17(29,19(23,24)25)16(28)26-13-7-8-15(27(30)31)14(9-13)18(20,21)22/h2-9,11,29H,10H2,1H3,(H,26,28)
  • Key:RETGATTXHQWSOT-UHFFFAOYSA-N

References
  1. Dukes M, Furr BJ, Hughes LR, Tucker H, Woodburn JR (2000). "Nonsteroidal progestins and antiprogestins related to flutamide". Steroids. 65 (10–11): 725–31. doi:10.1016/s0039-128x(00)00179-3. PMID 11108883. S2CID 9749394.
  2. Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 209–. ISBN 978-3-527-62330-3.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.